A federal intrusion that disrupts coverage for three-quarters of the population, requires tax hikes and spending cuts, and leads to less drug access hardly seems like a political winner. But neither is silence on the other side of the debate.
A single-payer pharmacare scheme would disrupt coverage for the 77 per cent of the population generally satisfied with the status quo, argues Sean Speer. Photograph courtesy of Victor Casale
As we approach the 2019 federal election campaign, we seem to be moving towards to a major policy conflict between political parties on pharmacare and the federal role.
People. Policy. Politics. This is an exclusive subscriber-only story.
Though many acknowledge Leslyn Lewis has demonstrated her political chops, her candidacy is still seen as a long shot in a race that some say will be driven by electability in the next general election.
'The core operating ideal within ... Ottawa is evidence-based policymaking and there are clearly other jurisdictions out there besides the U.S. that have done a better job in containing [the virus],' says Eric Miller.
Small Business Minister Mary Ng says the extent of her interactions with the organization was limited to that initial pitch, and did not extend to the since-cancelled contract for the student-grant program.